2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl benzoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl benzoate
• 英文别名: [2-oxo-4-(trifluoromethyl)chromen-7-yl] benzoate
• 化学式: C₁₇H₉F₃O₄
• mdl: MFCD02215452
• 分子量: 334.24
• InChiKey: LDHWSFNVZYGNHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] SMALL MOLECULE LIPID II INHIBITORS<br/>[FR] INHIBITEURS DE LIPIDE II À PETITE MOLÉCULE
  申请人：UNIV MARYLAND

  公开号：WO2017112668A1

  公开（公告）日：2017-06-29

  Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4- (dimethylamino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of Enterococci. It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.

  新合成的BAS00127538衍生物已被发现具有抗生素活性，并可对抗耐药细菌菌株。描述了含有这些化合物的化合物和药物组合物，并基于一种通用的支架结构。还描述了合成方法和使用这些化合物的方法。首选的化合物6jc48-1 ((E)-2,4-双(4-溴苯基)-6-(4-(二甲基氨基)苯乙烯基)吡啶硼四氟化物盐) 与脂质II结合亲和力高，其细胞毒性明显降低于BAS00127538，对肠球菌耐药菌株仍具有活性。它在血浆中稳定，具有显著改善的药代动力学性质，并在小鼠脓毒症模型中表现出体内有效性。
• Small molecule lipid II inhibitors
  申请人：University Of Maryland, Baltimore

  公开号：US10941114B2

  公开（公告）日：2021-03-09

  Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a genetic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

  已发现新合成的 BAS00127538 衍生物具有抗生素活性，并能对抗耐药细菌菌株。本文描述了含有这些化合物的化合物和药物组合物，它们都基于基因支架结构。此外，还介绍了这些化合物的合成方法和使用方法。优选化合物与脂质 II 结合的亲和力高，与 BAS00127538 相比细胞毒性明显降低，对肠球菌耐药菌株仍有活性。它们在血浆中稳定，药代动力学和药效学特性显著改善，在败血症小鼠模型中具有体内疗效。
• SMALL MOLECULE LIPID II INHIBITORS
  申请人：University of Maryland, Baltimore

  公开号：EP3393473A1

  公开（公告）日：2018-10-31
• Small Molecule Lipid II Inhibitors
  申请人：University of Maryland, Baltimore

  公开号：US20190002426A1

  公开（公告）日：2019-01-03

  Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4-(dimethyl-amino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of Enterococci . It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.